OhioGuidestone Expands Use of Greenspace Health's Measurement-Based Care Platform to Strengthen Mental Health Outcomes
The organization first introduced Greenspace's MBC platform in February 2025 through a limited four month pilot across 50 clinicians. Following strong clinical adoption and positive client engagement, OhioGuidestone has now scaled their MBC implementation organization-wide starting June 30, to include over 700 clinicians and supervisors across seven regions supporting over 15,000 additional clients.
'Measurement-Based Care is allowing us to fundamentally strengthen how we deliver care across every level of our organization,' said Kathleen Kern, PhD, Chief Clinical Officer at OhioGuidestone. 'With Greenspace, we can monitor real-time client progress, identify when additional support is needed and proactively intervene, and empower our clinicians with actionable data to guide treatment. Greenspace's MBC platform is helping us deliver meaningful, person-centered care, while also equipping our teams with the tools and confidence they need to support complex cases and achieve better outcomes.'
Greenspace's platform integrates directly into OhioGuidestone's existing clinical workflows, streamlining data collection and generating real-time insights that inform treatment plans and identify clients in need of additional support, including early warnings for suicidality and at-risk clients.
The platform has already demonstrated strong results in early implementation:
92% of therapists have active clients completing assessments
Over 5,000 assessments completed across nearly 1,000 clients
41% recovery rate in pediatric clients and 31% recovery rate for general clients experiencing depression, which is in line with median benchmarks of organizations adopting MBC.
OhioGuidestone has paired effective MBC technology with extensive clinician training to ensure measures are fully integrated into practice, supported by individualized coaching and ongoing leadership support.
'OhioGuidestone's commitment to both clinical excellence and operational leadership has been a driving force behind the success of this implementation,' said Simon Weisz, President of Greenspace Health. 'They have built an environment where new technology is leveraged to directly support client care, staff workflows, and long-term organizational growth. This initiative clearly demonstrates how Measurement-Based Care can transform the way mental health services are delivered, and OhioGuidestone is setting a strong example for the broader behavioral health community.'
OhioGuidestone's expansion signals a growing trend as community behavioral health providers seek scalable, technology-enabled care models that support quality improvement and ensure they are prepared for accreditation requirements and value-based care funding models. To learn more about Measurement-Based Care, please visit greenspacehealth.com.
About OhioGuidestone
With compassion and respect, OhioGuidestone helps people across the lifespan navigate the most difficult times of their lives. As the state's leader in community behavioral health care, we focus on the needs of the whole person, empowering them to take steps towards a healthier future. OhioGuidestone provides a complete continuum of prevention services and mental health and substance use treatment, focusing on responsive person-centered care delivered through telehealth and locations across the state. For more information about our services, visit ohioguidestone.org or call 1-844-622-5584.
About Greenspace Health
Greenspace transforms mental health services by improving the way that behavioral healthcare is accessed, measured and delivered. Their Measurement-Based Care Platform enables mental health providers and organizations to implement consistent, evidence-based measurement (often referred to as routine patient-reported outcome measures or PROMs) into their practice. This model is proven to significantly improve patient results while generating valuable data for organizations to enhance their quality of care. Greenspace's MBC solutions have been implemented across over 500 community and private clinics, hospitals, payors, insurers and healthcare systems, improving the patient experience and driving better-coordinated care and outcomes. To learn more about MBC, please visit greenspacehealth.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10-07-2025
- Yahoo
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in 'Eye-Bulging' Breast Cancer Patient
(PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care today announced updated results from its ongoing Phase 2 study of Bria-IMT™ in combination with check point inhibitor in patients with advanced metastatic breast cancer (MBC). BriaCell is pleased to report the sustained complete resolution of temporal lobe brain metastasis and continued orbital (behind the eye) tumor reduction after > 18 months of treatment in the Phase 2 study. The metastatic tumor initially caused proptosis –a visibly bulging of the eye. As previously reported, the heavily pre-treated MBC patient had demonstrated a complete resolution of a temporal lobe brain metastasis and a significant response in a right orbital metastasis at 8 months, then at 11 months. The patient has now maintained both responses for more than 18 months, with no evidence of brain tumor recurrence and ongoing tumor shrinkage in the orbital lesion. Figure 1: Bria-IMT treatment resulted in complete resolution of the right temporal lobe lesion and continued regression of the right orbital (behind the eye) tumor. The right temporal lobe lesion is no longer detectable on the images taken at 8 months (May 2024), 11 months (Aug 2024), and 20 months (May 2025).This patient had failed eight prior treatment regimens, including an antibody-drug conjugate (ADC), before initiating therapy with Bria-IMT plus checkpoint inhibition. She has now completed 29 treatment cycles and has been on BriaCell's Phase 2 study for over 21 months. Serial imaging at 8, 11, and now 20 months have confirmed no detectable disease in the right temporal lobe, along with continued response in the orbital lesion. Additionally, the patient's tumor markers have remained markedly reduced from baseline, further supporting the sustained radiologic response. 'These encouraging results continue to suggest that our novel Bria-IMT regimen may provide durable immunotherapeutic benefit in late-stage breast cancer patients with brain metastases who have exhausted other options,' stated Dr. William V. Williams, BriaCell's President & CEO. 'The long-term response observed in this patient reinforces the potential of Bria-IMT to improve outcomes while maintaining a favorable tolerability profile.' About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at Safe Harbor This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell's Bria-IMT regimen bringing relief to cancer patients whose medical needs remain unmet and the Bria-IMT regimen becoming a therapeutic option for metastatic breast cancer patients, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading 'Risk Factors' in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact:William V. Williams, MDPresident & CEO1-888-485-6340info@ Investor Relations Contact:investors@ A photo accompanying this announcement is available at lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Business Wire
08-07-2025
- Business Wire
OhioGuidestone Expands Use of Greenspace Health's Measurement-Based Care Platform to Strengthen Mental Health Outcomes
CLEVELAND--(BUSINESS WIRE)-- OhioGuidestone, Ohio's leader in community behavioral healthcare, announced today the expansion of its partnership with Greenspace Health, extending the use of its Measurement-Based Care (MBC) technology across the organization's behavioral health services to further improve their quality of care, client outcomes and clinician engagement. The organization first introduced Greenspace's MBC platform in February 2025 through a limited four month pilot across 50 clinicians. Following strong clinical adoption and positive client engagement, OhioGuidestone has now scaled their MBC implementation organization-wide starting June 30, to include over 700 clinicians and supervisors across seven regions supporting over 15,000 additional clients. 'Measurement-Based Care is allowing us to fundamentally strengthen how we deliver care across every level of our organization,' said Kathleen Kern, PhD, Chief Clinical Officer at OhioGuidestone. 'With Greenspace, we can monitor real-time client progress, identify when additional support is needed and proactively intervene, and empower our clinicians with actionable data to guide treatment. Greenspace's MBC platform is helping us deliver meaningful, person-centered care, while also equipping our teams with the tools and confidence they need to support complex cases and achieve better outcomes.' Greenspace's platform integrates directly into OhioGuidestone's existing clinical workflows, streamlining data collection and generating real-time insights that inform treatment plans and identify clients in need of additional support, including early warnings for suicidality and at-risk clients. The platform has already demonstrated strong results in early implementation: 92% of therapists have active clients completing assessments Over 5,000 assessments completed across nearly 1,000 clients 41% recovery rate in pediatric clients and 31% recovery rate for general clients experiencing depression, which is in line with median benchmarks of organizations adopting MBC. OhioGuidestone has paired effective MBC technology with extensive clinician training to ensure measures are fully integrated into practice, supported by individualized coaching and ongoing leadership support. 'OhioGuidestone's commitment to both clinical excellence and operational leadership has been a driving force behind the success of this implementation,' said Simon Weisz, President of Greenspace Health. 'They have built an environment where new technology is leveraged to directly support client care, staff workflows, and long-term organizational growth. This initiative clearly demonstrates how Measurement-Based Care can transform the way mental health services are delivered, and OhioGuidestone is setting a strong example for the broader behavioral health community.' OhioGuidestone's expansion signals a growing trend as community behavioral health providers seek scalable, technology-enabled care models that support quality improvement and ensure they are prepared for accreditation requirements and value-based care funding models. To learn more about Measurement-Based Care, please visit About OhioGuidestone With compassion and respect, OhioGuidestone helps people across the lifespan navigate the most difficult times of their lives. As the state's leader in community behavioral health care, we focus on the needs of the whole person, empowering them to take steps towards a healthier future. OhioGuidestone provides a complete continuum of prevention services and mental health and substance use treatment, focusing on responsive person-centered care delivered through telehealth and locations across the state. For more information about our services, visit or call 1-844-622-5584. About Greenspace Health Greenspace transforms mental health services by improving the way that behavioral healthcare is accessed, measured and delivered. Their Measurement-Based Care Platform enables mental health providers and organizations to implement consistent, evidence-based measurement (often referred to as routine patient-reported outcome measures or PROMs) into their practice. This model is proven to significantly improve patient results while generating valuable data for organizations to enhance their quality of care. Greenspace's MBC solutions have been implemented across over 500 community and private clinics, hospitals, payors, insurers and healthcare systems, improving the patient experience and driving better-coordinated care and outcomes. To learn more about MBC, please visit
Business Wire
17-06-2025
- Business Wire
Zetagen Therapeutics Announces Peer-reviewed Publication of In-Vivo Dose Optimization Findings for ZetaMast™ (Zeta-MBC-005) for Triple Negative Breast Cancer Liver Metastases
SYRACUSE, N.Y.--(BUSINESS WIRE)--Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing first-of-its-kind targeted therapies for primary and metastatic breast cancer, announced today the peer-reviewed publication in PLOS-One of their dose optimization in-vivo study results of ZetaMast™ (Zeta-MBC-005). Zetagen identified two concentrations of ZetaMast™ (Zeta-MBC-005) which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin. ' Patients with disseminated metastatic breast cancer involving the liver, face a poor prognosis and new approaches are urgently needed, ' stated Debasish Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. ' Although some therapies have been designed for direct administration for liver metastases, they have not demonstrated efficacy in significantly improving survival. ZetaMast™ is an innovative therapeutic approach that has demonstrated systemic biological effects potentially extending beyond liver metastases in preclinical models, offering promising potential to enhance outcomes in this setting.' ZetaMast™ (Zeta-MBC-005) Increased Survival in a Mouse Xenograft Liver Metastases Model. The 4T1, TNBC cell line, tagged with luc2 luciferase (4T1-luc2), was implanted directly into the liver of BALB/c mice. Seven days after tumor inoculation, mice were treated with various concentrations via a single administration of ZetaMast™ (Zeta-MBC-005) (30-, 60-, 120-, 180-, 240-, or 480-μg) in combination with 5-mg/kg doxorubicin. Mice in the Control group received 5 mg/kg of doxorubicin and the ZetaMast™ (Zeta-MBC-005) carrier without Zetagen's small molecule, administered every 72-hours. ZetaMast™ (Zeta-MBC-005) has the ability to deliver Zetagen's small molecules intratumorally as well as other therapies, avoiding off-target side effects. 'Effective locoregional therapies are likely the key to reducing breast cancer mortality for patients with disseminated metastatic disease and increasing 5-year survival above 31%. If treatments like ZetaMast™ (Zeta-MBC-005) can be given when and where needed, increasing the duration of overall tumor control, which may be enough to tip the balance towards a favorable impact on survival,' stated Bryan S. Margulies, MS, Ph.D., CSO of Zetagen. To view the ZetaMAST™ (Zeta-MBC-005) dose optimization study results go to About ZetaMAST™ (Zeta-MBC-005) ZetaMast™ (Zeta-MBC-005) is a proprietary drug eluting carrier designed for locoregional administration, controlled release of two small molecules in the treatment of multifocal, unresectable, liver metastases from breast cancer with the potential to increase survival rates. The USPTO has granted Zetagen a 'Composition of Matter' patent for ZetaMast™ (Zeta-MBC-005), and Zetagen has also submitted a filing to the FDA for Orphan Drug Designation. Zetagen is finalizing preparations for an FDA IND submission this fall, with a Phase 1b clinical trial set to commence early 2026. About Zetagen Therapeutics Zetagen has three novel drugs in development, ZetaMet™ (Zeta-BC-003), for the treatment of metastatic breast cancer to bone, ZetaMast™ (Zeta-MBC-005) for breast cancer liver metastases (BCLM), and (NEW) ZetaPrime™ (Zeta-PBC-007) for the treatment of primary HR+ breast cancer, all with inspiring results. To learn more, visit The FDA has acknowledged Zetagen's innovative research with multiple Breakthrough Designations, notably ZetaMet™ (Zeta-BC-003). Under FDA and Health Canada (HC) approval through the Expanded Access (Compassionate Use) programs, Zetagen has treated eight patients with ZetaMet™ (Zeta-BC-003), with results featured in several peer-reviewed journals. Furthermore, Zetagen has completed enrollment for its Phase 2a open-label clinical trial focused on treating metastatic breast cancer in the spine. Zetagen Upcoming Events Zetagen will attend the 2025 San Antonio Breast Cancer Symposium (SABCS). Forward-Looking Statements This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
